Share on

Latin America Dendritic Cell Cancer Market Vaccines By Product Type (CreaVax, Sipuleucel-T (Provenge), Others), By End User (Pediatrics, Adults), By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2022 to 2027)

Published: March, 2023
ID: 5269
Pages: 145
Formats: report pdf report excel report power bi report ppt

The Latin America Dendritic Cell Cancer Vaccines market size was around USD XX billion in 2017. It is expected to grow at a CAGR of XX% to reach USD XX billion by 2022. It captures XX% of the global market share.

Leukocytes of a very rare kind are termed as Dendritic cells (DCs). They are highly effective in providing antigens to T cells. If kept isolated and administered tumour antigen ex vivo then DCs if administered as a cellular vaccine are found to enhance immunity in animals. They are found in lymphoid organs. Enhancement in immunity comes from the secretion of cytokines. As of now cancer treatment relies heavily on radiation, chemo etc. DCs are adaptable and hence provide flexibility in treatment of different kinds of cancer.

Increasing number of cases of people suffering from cancer, better availability of treatment methods, rising healthcare expenditure, savoury government policies and heavy investments in R&D, and improving success rates of clinical trials are the primary factors driving the growth of this market. Augmenting geriatric population, rapid advancements in technology and the ability to combat several cancer antigens are the secondary factors fuelling market growth.

Little or no penetration of DC vaccines in remote areas, strict administrative and regulatory frameworks, and ambiguity over the results of the clinical trials on these vaccines are the primary restraints of market growth.

The market is segmented by end user and product type. Classification by end user entails paediatrics and adults. Classification by product type entails CreaVax, Sipuleucel-T (Provenge), and others. Provenge was the first DC vaccine which was introduced in the market. So naturally it follows that it is the market leader and is expected to remain so till the end of the forecast period. It treats melanoma, prostate cancer etc. It was approved by the FDA nearly seven years ago.

Classification by geography entails Brazil, Chile, Argentina, and others. Latin America continues to lag and will remain the least attractive markets all through the forecast period.

Key players in the market include 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.


Please wait. . . . Your request is being processed

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]